{"id":818849,"date":"2026-08-19T14:38:12","date_gmt":"2026-08-19T14:38:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/818849\/"},"modified":"2026-08-19T14:38:12","modified_gmt":"2026-08-19T14:38:12","slug":"piramal-pharma-acquires-majority-stake-in-yapan-bio","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/818849\/","title":{"rendered":"Piramal Pharma Acquires Majority Stake in Yapan Bio"},"content":{"rendered":"<p class=\"has-cyan-bluish-gray-background-color has-background\">Editor\u2019s Take: CEO Peter DeYoung has played a major role in transforming Piramal Pharma into a more focused, globally integrated pharmaceutical company. <a href=\"https:\/\/www.contractpharma.com\/ceo-spotlight-peter-deyoung\/\" rel=\"nofollow noopener\" target=\"_blank\">Revisit Contract Pharma\u2019s exclusive interview with DeYoung from 2022.<\/a><\/p>\n<p><a href=\"https:\/\/www.piramalpharma.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Piramal Pharma Ltd. (PPL)<\/a> has acquired an incremental 40.67% stake in <a href=\"https:\/\/www.yapanbio.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Yapan Bio Private Limited<\/a>, a Hyderabad-based CDMO specializing in vaccines and biologics, for an aggregate cash consideration of $7.95 million. As a result of this transaction, PPL now owns 74% of Yapan Bio\u2019s equity, making Yapan Bio a subsidiary of PPL.<\/p>\n<p>This acquisition marks a step forward in PPL\u2019s long-term plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary\u2019s advanced large molecule capabilities into its integrated service offering, enabling it to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of <a href=\"https:\/\/www.contractpharma.com\/company-profile\/piramal-pharma-solutions-477700\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Piramal Pharma Solutions<\/a> (PPS), the CDMO arm of PPL.<\/p>\n<p>This acquisition also further enhances ADCelerate, PPS\u2019s fixed-price, integrated platform that streamlines Phase I ADC development from R&amp;D to GMP in as little as 12 months, and reinforces PPL\u2019s ability to deliver life-saving ADCs to market with speed and consistency.<\/p>\n<p>\u201cThis strategic investment doesn\u2019t just fuel our long-term growth; it also puts Patient Centricity into action,\u201d said Peter DeYoung, CEO, Piramal Global Pharma. \u201cBy integrating Yapan Bio\u2019s specialized expertise into our global network, we\u2019re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.\u201d<\/p>\n<p>Other Pharma Industry Acquisitions<\/p>\n<p>Check out Contract Pharma\u2019s\u00a0<a href=\"https:\/\/www.contractpharma.com\/exclusives\/2024-pharmaceutical-industry-mergers-acquisitions-roundup\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Pharmaceutical Industry Mergers &amp; Acquisitions Roundup<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: CEO Peter DeYoung has played a major role in transforming Piramal Pharma into a more focused,&hellip;\n","protected":false},"author":2,"featured_media":818850,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-818849","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/818849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=818849"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/818849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/818850"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=818849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=818849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=818849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}